SequelSEC

IRIDEX CORP IRIX

Electromedical & Electrotherapeutic Apparatus · CIK 0001006045 · Fiscal year ends 0103

AnnualQuarterlyTTM
Revenue
$51.57M
Fiscal year ended 2026-07-04
Operating income
-$2.78M
Fiscal year ended 2026-07-04
Free cash flow
-$2.00M
Fiscal year ended 2026-07-04

Valuation, from the filing

Public float$14.24MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-27
Float per share$0.82Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-27, not today, and each multiple below it uses the figures for the fiscal year ending 2026-01-03 — the year that filing covered.

How this compares in its industry

Percentile among the Electromedical & Electrotherapeutic Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin36.5%15th
CapEx / revenue0.3%15th
R&D / revenue7.0%23th
Operating margin-4.9%64th
Net margin-8.4%63th
Revenue YoY growth8.2%43th
FCF margin-4.3%55th
Current ratio1.91x47th

IRIDEX CORP (IRIX) reported revenue of $51.57M and net income of -$3.55M for the fiscal year ended 2026-07-04. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IRIDEX CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

IRIDEX CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-04
Revenue$51.57M
Cost of revenue$33.05M
Gross profit$18.53M
Operating income-$2.78M
Net income-$3.55M
Research & development$3.76M
Weighted-average diluted sharesUnavailable
Pretax income-$3.40M
Income tax expense$152.00K
Diluted EPSUnavailable
Selling, general & administrative$17.54M
General & administrative$7.05M
Selling & marketing$10.49M

Balance

IRIDEX CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-04
Cash & equivalents$4.68M
Total assets$27.26M
Current assets$23.96M
Total liabilities$23.62M
Current liabilities$13.17M
Total equity incl. NCI$3.64M
Temporary (mezzanine) equityUnavailable
Inventory$9.75M
Accounts receivable$5.67M
Goodwill$965.00K
Long-term debtUnavailable
Accounts payable$6.65M

Cash flow

IRIDEX CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-04
Operating cash flow-$1.73M
Capital expenditures$270.00K
Investing cash flow-$270.00K
Financing cash flow-$100.00K
Net change in cash-$2.10M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$447.00K

Derived

IRIDEX CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-04
Free cash flow-$2.00M
Gross margin35.9%
Operating margin-5.4%
FCF margin-3.9%
SBC / revenueUnavailable
Current ratio1.82x
Revenue YoY growth3.7%
Net margin-6.9%
R&D / revenue7.3%
CapEx / revenue0.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IRIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-18View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-04-02View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ADMT AXGN BLFS CBLL CNMD CV ECOR ELMD ESMC FOCL GTHP HCIL

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.